Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Activation of ataxia telangiectasia muted under experimental models and human Parkinson's disease.

Authors: Camins, A  Pizarro, JG  Alvira, D  Gutierrez-Cuesta, J  De la Torre, AV  Folch, J  Sureda, FX  Verdaguer, E  Junyent, F  Jordan, J  Ferrer, I  Pallas, M 
Citation: Camins A, etal., Cell Mol Life Sci. 2010 Nov;67(22):3865-82. doi: 10.1007/s00018-010-0408-5. Epub 2010 May 26.
Pubmed: (View Article at PubMed) PMID:20502937
DOI: Full-text: DOI:10.1007/s00018-010-0408-5

In the present study we demonstrated that neurotoxin MPP(+)-induced DNA damage is followed by ataxia telangiectasia muted (ATM) activation either in cerebellar granule cells (CGC) or in B65 cell line. In CGC, the selective ATM inhibitor KU-55933 showed neuroprotective effects against MPP(+)-induced neuronal cell loss and apoptosis, lending support to the key role of ATM in experimental models of Parkinson's disease. Likewise, we showed that knockdown of ATM levels in neuroblastoma B65 cells using an ATM-specific siRNA attenuates the phosphorylation of retinoblastoma protein without affecting other cell-cycle proteins involved in the G(0)/G(1) cell-cycle phase. Moreover, we demonstrated DNA damage, in human brain samples of PD patients. These findings support a model in which MPP(+) leads to ATM activation with a subsequent DNA damage response and activation of pRb. Therefore, this study demonstrates a new link between DNA damage by MPP(+) and cell-cycle re-entry through retinoblastoma protein phosphorylation.


Disease Annotations
Gene Ontology Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 10053605
Created: 2015-07-15
Species: All species
Last Modified: 2015-07-15
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.